Nasonex (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasonex, is a corticosteroid presented as a nasal spray for nasal use. It treats allergic rhinitis and nasal polyps in adults and children as directed by a healthcare professional.

GNH USA supplies Nasonex as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasonex (mometasone furoate) is a nasal corticosteroid used to manage inflammatory conditions of the nasal passages.

Allergic rhinitis (perennial): reduces nasal congestion, itching and sneezing. Seasonal allergic rhinitis: controls symptoms triggered by seasonal allergens. Nasal polyps: decreases polyp size and improves nasal airflow.

Nasonex may cause a range of local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleeds) - Throat irritation or dryness - Cough - Altered taste or odor perception

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use - Glaucoma or cataract formation - Severe or persistent nosebleeds - Opportunistic fungal infection of the nasal passages - Systemic immunosuppression leading to increased infection risk - Hypersensitivity reactions such as angioedema

Before using Nasonex, consider the following safety measures.

Prescribe only as directed: follow the healthcare professional’s instructions for frequency and duration. Avoid in hypersensitivity: do not use if the patient has known allergy to mometasone furoate or any component of the formulation. Caution after nasal surgery or trauma: defer use until healing is complete to reduce risk of bleeding. Monitor for adrenal effects: prolonged high‑dose therapy may affect endogenous cortisol production. Use with care in glaucoma or cataract patients: intra‑ocular pressure should be monitored. Store at room temperature: keep in the original container, protect from moisture and direct heat.

Mometasone furoate can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase systemic exposure. - Concurrent intranasal corticosteroids can raise the risk of systemic glucocorticoid effects. - Systemic immunosuppressants may amplify infection risk when combined.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids may add to overall glucocorticoid load. - Live vaccines may have reduced efficacy; timing should be coordinated. - Antifungal agents metabolized by CYP3A4 may require monitoring of levels.